Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation

Transplant Infectious Disease

Volumn 10, Issue 3, 2008, Pages 162-167

  Mihu, C N ^a   King, E ^a   Yossepovitch, O ^a   Taur, Y ^a   Jakubowski, A ^a   Pamer, E ^a   Papanicolaou, G A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; Late aspergillosis; Mortality; Risk factors; T cell depleted

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; GANCICLOVIR; ITRACONAZOLE; MICAFUNGIN; PENTAMIDINE; VORICONAZOLE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHICKENPOX; COHORT ANALYSIS; DATA BASE; DRUG INDICATION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; STATISTICAL ANALYSIS; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; ASPERGILLOSIS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; INFANT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 43949095836     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2007.00272.x     Document Type: Article

References (11)

1. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004 34 : 1115 1121.
2. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002 15 : 4358 4366.
3. Barker JN, Hough RE, van Burik JA, et al. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol Blood Marrow Transplant 2005 11 : 362 370.
4. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
5. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995 15 : 825 828.
6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002 34 : 909 917.
7. Broers AE, van der Holt B, Haze S, et al. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation. Exp Hematol 2005 33 : 912 919.
8. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002 99 : 4357 4363.
9. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006 43 : 16 24.
10. Kojima R, Tateishi U, Kami M, et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005 11 : 506 511.
11. Leung AN, Gosselin MV, Napper CH, et al. Pulmonary infections after bone marrow transplantation: clinical and radiographic findings. Radiology 1999 210 : 699 710.